Serum interleukin-16 levels in patients with nasal polyposis


  • Presented at the 33rd Turkish National Otorhinolaryngology and Head and Neck Surgery Congress, Antalya, Turkey, October 26–30, 2011.

  • This work was supported by the Gazi University Scientific Research Fund. The authors have no other funding, financial relationships, or conflicts of interest to disclose.



Several inflammatory and allergic disorders have been reported to correlate with interleukin-16 (IL-16). IL-16 is a highly potent chemotactic and chemoattractant molecule for eosinophils. Nasal polyposis (NP) has an inflammatory basis, and eosinophilia is a common finding in polyp tissue. In this study, we aimed to determine serum IL-16 levels in NP patients.

Study Design:

Prospective controlled study in a tertiary academic hospital.


Peripheral blood samples were obtained and used for serologic studies with enzyme-linked immunosorbent assay kits to determine IL-16 levels.


The study and the control groups consisted of 17 and 10 patients, respectively. Mean serum IL-16 levels were significantly higher in the study group when compared to the control group (447.9 pg/mL vs. 260.2 pg/mL) (P < .001).


Serum IL-16 levels are significantly elevated in NP patients. This finding may represent identification of a valuable serum biomarker and potential therapeutic target in NP patients.